NCT05479448 Predictive Factors for Treatment Response in Patients With Newly-diagnosed Polymyalgia Rheumatica and Giant Cell Arteritis
| NCT ID | NCT05479448 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | Polymyalgia Rheumatica (PMR) |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2022-06-03 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2022-06-03 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective study is to explore different predictive factors for response to steroid treatment in patients with PMR and/or GCA. It evaluates the association of endogenous GC suppression (plasma and urinary cortisol and cortisone) to the responsiveness of PMR/GCA to GCs.
Eligibility Criteria
Inclusion Criteria: * Patients with diagnosis of PMR according to the 2012 provisional classification criteria and GCA according to published criteria * Consent to participate in the SCQM database * Treatment according to our standardized regimes Exclusion Criteria: * Treatment with Tocilizumab, MTX or other disease modifying medications at inclusion * History of GCA and PMR in the past * Inability to give informed consent
Contact & Investigator
Thomas Daikeler, Prof. Dr. med.
PRINCIPAL INVESTIGATOR
Department of Rheumatology University Hospital Basel
Frequently Asked Questions
Who can join the NCT05479448 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Polymyalgia Rheumatica (PMR). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05479448 currently recruiting?
Yes, NCT05479448 is actively recruiting participants. Contact the research team at Thomas.Daikeler@usb.ch for enrollment information.
Where is the NCT05479448 trial being conducted?
This trial is being conducted at Basel, Switzerland.
Who is sponsoring the NCT05479448 clinical trial?
NCT05479448 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Thomas Daikeler, Prof. Dr. med. at Department of Rheumatology University Hospital Basel. The trial plans to enroll 30 participants.